AREB vs CRBP vs AGIO vs RCUS

For growth investors, Agios Pharmaceuticals, Inc.

(AGIO) is the stronger pick with 48. 0% revenue growth year-over-year, versus -16. 6% for American Rebel Holdings, Inc. (AREB). Analysts rate Corbus Pharmaceuticals Holdings, Inc. (CRBP) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Arcus Biosciences, Inc.

(RCUS) delivered a total return of -18. 6%, compared to -100. 0% for American Rebel Holdings, Inc. (AREB). Over 10 years, the gap is even starker: RCUS returned +45. 9% versus AREB's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), American Rebel Holdings, Inc.

(AREB) is the lower-risk stock at 1. 05β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 85% more volatile than AREB relative to the S&P 500. On balance sheet safety, Corbus Pharmaceuticals Holdings, Inc. (CRBP) carries a lower debt/equity ratio of 1% versus 52% for American Rebel Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Agios Pharmaceuticals, Inc.

(AGIO) is pulling ahead at 48. 0% versus -16. 6% for American Rebel Holdings, Inc. (AREB). On earnings-per-share growth, the picture is similar: American Rebel Holdings, Inc. grew EPS 58. 8% year-over-year, compared to -161. 2% for Agios Pharmaceuticals, Inc.. Over a 3-year CAGR, AGIO leads at 56. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Corbus Pharmaceuticals Holdings, Inc.

(CRBP) is the more profitable company, earning 0. 0% net margin versus -764. 0% for Agios Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CRBP leads at 0. 0% versus -873. 9% for AGIO. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, American Rebel Holdings, Inc.

(AREB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 05)). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AREB: -100. 0%, RCUS: +45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (AREB (Consumer Cyclical) and CRBP (Healthcare) and AGIO (Healthcare) and RCUS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: AREB is a small-cap quality compounder stock; CRBP is a small-cap quality compounder stock; AGIO is a small-cap high-growth stock; RCUS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.